BCRX : Summary for BioCryst Pharmaceuticals, Inc. - Yahoo Finance

Canadian Markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.33-0.16 (-2.47%)
At close: 4:00PM EDT

6.33 0.00 (0.00%)
After hours: 4:54PM EDT

People also watch
NVAXHEBVICLARRYALNY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close6.49
Open6.45
Bid6.21 x 100
Ask6.75 x 800
Day's Range6.32 - 6.56
52 Week Range2.49 - 9.25
Volume614,449
Avg. Volume1,725,556
Market Cap508.79M
Beta2.78
PE Ratio (TTM)-8.46
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    BioCryst to Announce First Quarter 2017 Financial Results May 4

    RESEARCH TRIANGLE PARK, N.C., April 24, 2017-- BioCryst Pharmaceuticals, Inc. today announced that its first quarter 2017 financial results will be reported on Thursday, May 4 th, 2017.. BioCryst will ...

  • American City Business Journals13 days ago

    After announcing a $45M public offering, BioCryst to launch new trial

    On the heels of announcing a $45 million secondary public offering of the company’s common stock last month, Durham-based BioCryst Pharmaceuticals (BCRX) plans to move forward with a new trial for its hereditary angioedema (HAE) therapy BCX7353. The company said it will explore a new oral liquid for treating acute attacks in patients with hereditary angioedema. It added that it has received “initial regulatory approvals in Europe” for the clinical trial.

  • GlobeNewswire14 days ago

    BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks

    RESEARCH TRIANGLE PARK, N.C., April 12, 2017-- BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today ...